
|
|
||||||
|
Medications
![]() ![]()
|
||||||
Following Your Hepatitis C Treatment Program
|
||||||
|
The goal when taking combination therapy is to get rid of the
Clearing the virus may also bring down the long-term risk of liver cancer.
To get the best effect possible, you may need to be on the combination therapy for up to a year. If you stop taking the medications before your treatment program is finished or do not take the right amount (or if you do not take it as often as directed) you will not get the full effect of the medication.
Studies show that about 56 to 60 percent of people who complete their treatment with peginterferon and ribavirin have a successful response -- called a sustained virological response, or SVR. This means that 6 months after finishing the treatment, no virus RNA is detected in their blood.
One important factor in how people respond to combination therapy is the type of the virus causing the hepatitis C. This is also known as the genotype. There are 6 main genotypes of the hepatitis C virus: genotypes 1, 2, 3, 4, 5, and 6. Genotypes 1, 2, and 3 are the most common in the United States. People with genotype 1 generally respond less well to combination therapy than people with genotypes 2 or 3. Additional factors, such as race and age, can also affect how well a person responds to the therapy. Other eMedTV articles provide more detailed information about:
Other factors that may affect the success of a person's hepatitis C treatment program include:
People with a low level of virus, and those with very little scarring on their liver before beginning treatment, tend to respond better to combination therapy.
Because every situation is different, your response to treatment for hepatitis C will depend on several of these factors. Your healthcare provider can discuss your individual situation with you in more detail.
| |||
| Referring Pages | Articles |